Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| REF/2014/11/007981 | Registry Identifier | Clinical Trial registry of India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a retrospective study in adult patients with cirrhosis and grade 3 or 4 HE (West Haven Criteria) to evaluate the effectiveness and safety of lactulose retention enema in the treatment of deep grade HE (West Haven Criteria). The study will be conducted retrospectively in a multi center of a multispecialty tertiary care hospital in India, in which lactulose retention enema is the mainstay of management of cirrhotic patients with grade 3 or 4 HE (West Haven criteria). Dosing of lactulose retention enema in this study will be done according to the dosing described for rectal administration of lactulose (India): 300ml of lactulose mixed with 700ml of potable water to be used as a retention enema; the enema is to be retained for 30-60 minutes and repeated every 4-6 hours until the patient is able to take oral medication. This treatment regime is also the standard protocol of management of deep grade HE (West Haven criteria) in the study centers. The standard treatment protocol of deep grade HE (West Haven criteria) of the study centers will also ensure that all known contraindications of lactulose will be respected before administration of lactulose retention enema to the study patients. The retrospective hospital records of the patient population of interest within the past 6 months will be identified, and these records will be used to collect data required for analysis.
Data to be collected:
Data that would be collected for the study as part of retrospective chart review:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with cirrhosis (grade 3 & 4 per west haven cr.) | Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Complete Reversal | Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema | 24 hrs |
| Complete Reversal | Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema | 48 hrs |
| Measure | Description | Time Frame |
|---|---|---|
| Hepatic Encephalopathy (HE) Grade Shift at 24 and 48 Hours | Grade shift at 24 and 48 hours - from baseline to 24 and 48 hours post administration of lactulose retention enema. Complete reversal of deep grade HE is defined as subjects having HE grade=\ |
| Measure | Description | Time Frame |
|---|---|---|
| Safety of Lactulose Retention Enema (Number of Adverse Drug Reactions & Complications). | Safety of Lactulose retention enema (number of adverse drug reactions & complications). Complications pertinent to lactulose retention enema are in reference to potential adverse effects associated with the use of rectal device associated with the application of the lactulose retention enema kit. | Chart Review of Events over 48 Hour Period |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Retrospective study - data charts of the cirrhotic patients having grade III and IV and who were administered lactulose enema will be reviewed.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dyotona Roy-Sengupta | Abbott | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medanta Hospital | Gurgaon | 122001 | India | |||
| Research facility ORG-000333 |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Patients With Cirrhosis (Grade 3 & 4 Per West Haven cr.) | Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| HE Grade shift at 24 hrs and HE Grade shift at 48 hrs |
| Time to Complete Reversal | Time to complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) HE after administration of lactulose retention enema | up to 48 hrs |
| Mortality | Mortality in patients treated with lactulose retention enema | within 48 hrs |
| Reduction in Blood Ammonia Level | Change from baseline was calculated at the end of treatment by using following formula wherever applicable: Change from baseline = Blood ammonia level at the end of treatment - Blood ammonia level at baseline | reported at 48 hrs |
| Duration of Hospital Stay | upto 30 days of hospital admission |
| Gurgaon |
| 122001 |
| India |
| Sir Ganga Ram Hospital | New Delhi | 110060 | India |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Patients With Cirrhosis (Grade 3 & 4 Per West Haven cr.) | Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||||
| Region of Enrollment | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Complete Reversal | Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema | Posted | Number | 95% Confidence Interval | percentage of participants | 24 hrs |
|
|
| ||||||||||||||||||||||||||
| Primary | Complete Reversal | Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema | Posted | Number | 95% Confidence Interval | percentage of participants | 48 hrs |
|
| |||||||||||||||||||||||||||
| Secondary | Hepatic Encephalopathy (HE) Grade Shift at 24 and 48 Hours | Grade shift at 24 and 48 hours - from baseline to 24 and 48 hours post administration of lactulose retention enema. Complete reversal of deep grade HE is defined as subjects having HE grade=\ | Posted | Number | percentage of participants | HE Grade shift at 24 hrs and HE Grade shift at 48 hrs |
|
| ||||||||||||||||||||||||||||
| Secondary | Time to Complete Reversal | Time to complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) HE after administration of lactulose retention enema | Posted | Mean | Standard Deviation | Hours | up to 48 hrs |
|
| |||||||||||||||||||||||||||
| Secondary | Mortality | Mortality in patients treated with lactulose retention enema | Posted | Count of Participants | Participants | within 48 hrs |
|
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Safety of Lactulose Retention Enema (Number of Adverse Drug Reactions & Complications). | Safety of Lactulose retention enema (number of adverse drug reactions & complications). Complications pertinent to lactulose retention enema are in reference to potential adverse effects associated with the use of rectal device associated with the application of the lactulose retention enema kit. | Posted | Number | number of events | Chart Review of Events over 48 Hour Period |
|
| ||||||||||||||||||||||||||||
| Other Pre-specified | Reduction in Blood Ammonia Level | Change from baseline was calculated at the end of treatment by using following formula wherever applicable: Change from baseline = Blood ammonia level at the end of treatment - Blood ammonia level at baseline | The ammonia levels were available at baseline for 28 patients where as the last observed blood ammonia level after administration of lactulose enema was available for 4 patients. Thus the change from baseline was calculated for 4 patients. The Change value = Visit value - Baseline Value | Posted | Mean | Standard Deviation | Mcg/DL | reported at 48 hrs |
|
| ||||||||||||||||||||||||||
| Other Pre-specified | Duration of Hospital Stay | Posted | Mean | Standard Deviation | hours | upto 30 days of hospital admission |
|
|
|
Not provided
As this study was a retrospective chart review of 50 patients who were treated with lactulose enema, only (S)ADRs and complications were collected. Thus, the total of participants at risk were 50 for ADRs and complications. Complications pertinent to lactulose retention enema are in reference to potential adverse effects associated with the use of rectal device associated with the application of the lactulose retention enema kit.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Patients With Cirrhosis (Grade 3 & 4 Per West Haven cr.) | Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema | 6 | 50 | 0 | 50 | 3 | 50 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhea and Abdominal discomfort | Gastrointestinal disorders | Only ADRs and complications were collected. Observed non serious ADRs are either considered to be sufficiently described in the section on undesirable effects in local label and/or associated with the method of administration as a retention enema |
| ||
| Abdominal fullness and discomfort | Gastrointestinal disorders | Only ADRs and complications were collected. Observed non serious ADRs are either considered to be sufficiently described in the section on undesirable effects in local label and/or associated with the method of administration as a retention enema |
| ||
| Mild rectal bleed | Injury, poisoning and procedural complications | Only ADRs and complications were collected. Observed non serious ADRs are either considered to be sufficiently described in the section on undesirable effects in local label and/or associated with the method of administration as a retention enema |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Shubhangi Desai | Abbott | +91 22 7175 7408 | shubhangi.desai@abbott.com |
| ID | Term |
|---|---|
| D006501 | Hepatic Encephalopathy |
| D008224 | Lymphoma, Follicular |
| ID | Term |
|---|---|
| D017093 | Liver Failure |
| D048550 | Hepatic Insufficiency |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
|
| Title | Denominators | Categories |
|---|
|
| Denominators |
|---|
| Categories |
|---|
|
|
|
|